Pattern Anlysis of Risk-Reducing Strategies in Unaffected Korean BRCA1/2 Mutation Carriers.

IF 2.8 4区 医学 Q2 ONCOLOGY Current oncology Pub Date : 2024-11-01 DOI:10.3390/curroncol31110499
Dabin Kim, Jai Min Ryu, Sang-Ah Han, Zisun Kim, Sung-Won Kim
{"title":"Pattern Anlysis of Risk-Reducing Strategies in Unaffected Korean <i>BRCA1/2</i> Mutation Carriers.","authors":"Dabin Kim, Jai Min Ryu, Sang-Ah Han, Zisun Kim, Sung-Won Kim","doi":"10.3390/curroncol31110499","DOIUrl":null,"url":null,"abstract":"<p><p>The lifetime risk of breast and ovarian cancer increases substantially for individuals with mutations in <i>BRCA1/2</i>. The evidence indicates that <i>BRCA1/2</i> mutation carriers benefit from early cancer detection and prevention strategies. However, data on the patterns of risk-reducing interventions are lacking. This study investigated the patterns of surveillance and risk-reducing interventions among unaffected <i>BRCA1/2</i> mutation carriers. A cohort of unaffected <i>BRCA1/2</i> mutation carriers was identified from the Korean Hereditary Breast cAncer (KOHBRA) study database, and a telephone survey was conducted. The survey included questions on the incidence of new cancers, patterns of cancer (breast, ovarian, prostate, other) surveillance, chemoprevention, risk-reducing surgery, and reasons for participating in risk-reducing strategies. Between November 2016 and November 2020, 192 <i>BRCA1/2</i> mutation carriers were contacted, of which 83 responded. After excluding 37 responders who refused to participate, 46 participants (15 males, 31 females) were included in the analysis. The mean ± SD follow-up time was 103 ± 17 months (median 107, range 68~154), and the mean ± SD age was 31 ± 8 years. Ten <i>BRCA1/2</i> mutation carriers developed breast cancer, one developed ovarian cancer, and three developed other cancers. Six <i>BRCA1/2</i> mutation carriers (19.4%) underwent annual breast cancer surveillance as recommended by guidelines, while none underwent ovarian or prostate cancer surveillance. Three carriers (9.7%) used chemoprevention for breast cancer. Risk-reducing salpingo-oophorectomy was performed on only one <i>BRCA1/2</i> mutation carrier. The rates of breast/ovarian cancer surveillance, chemoprevention, and risk-reducing surgery were low among unaffected Korean <i>BRCA1/2</i> mutation carriers. Given this cohort's relatively high risk of developing breast cancer, strategies to encourage active participation in risk reduction are needed.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6767-6777"},"PeriodicalIF":2.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592990/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol31110499","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The lifetime risk of breast and ovarian cancer increases substantially for individuals with mutations in BRCA1/2. The evidence indicates that BRCA1/2 mutation carriers benefit from early cancer detection and prevention strategies. However, data on the patterns of risk-reducing interventions are lacking. This study investigated the patterns of surveillance and risk-reducing interventions among unaffected BRCA1/2 mutation carriers. A cohort of unaffected BRCA1/2 mutation carriers was identified from the Korean Hereditary Breast cAncer (KOHBRA) study database, and a telephone survey was conducted. The survey included questions on the incidence of new cancers, patterns of cancer (breast, ovarian, prostate, other) surveillance, chemoprevention, risk-reducing surgery, and reasons for participating in risk-reducing strategies. Between November 2016 and November 2020, 192 BRCA1/2 mutation carriers were contacted, of which 83 responded. After excluding 37 responders who refused to participate, 46 participants (15 males, 31 females) were included in the analysis. The mean ± SD follow-up time was 103 ± 17 months (median 107, range 68~154), and the mean ± SD age was 31 ± 8 years. Ten BRCA1/2 mutation carriers developed breast cancer, one developed ovarian cancer, and three developed other cancers. Six BRCA1/2 mutation carriers (19.4%) underwent annual breast cancer surveillance as recommended by guidelines, while none underwent ovarian or prostate cancer surveillance. Three carriers (9.7%) used chemoprevention for breast cancer. Risk-reducing salpingo-oophorectomy was performed on only one BRCA1/2 mutation carrier. The rates of breast/ovarian cancer surveillance, chemoprevention, and risk-reducing surgery were low among unaffected Korean BRCA1/2 mutation carriers. Given this cohort's relatively high risk of developing breast cancer, strategies to encourage active participation in risk reduction are needed.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
未受影响的韩国 BRCA1/2 基因突变携带者的风险降低策略模式分析。
BRCA1/2 基因突变者终生罹患乳腺癌和卵巢癌的风险大大增加。有证据表明,BRCA1/2 基因突变携带者可从早期癌症检测和预防策略中获益。然而,有关降低风险干预模式的数据却很缺乏。本研究调查了未受影响的 BRCA1/2 基因突变携带者的监测和降低风险干预模式。研究人员从韩国遗传性乳腺癌(KOHBRA)研究数据库中找到了一批未受影响的 BRCA1/2 基因突变携带者,并进行了电话调查。调查内容包括新癌症发病率、癌症(乳腺癌、卵巢癌、前列腺癌、其他癌症)监测模式、化学预防、降低风险手术以及参与降低风险策略的原因等问题。2016 年 11 月至 2020 年 11 月期间,共联系了 192 名 BRCA1/2 基因突变携带者,其中 83 人做出了回应。在排除 37 名拒绝参与的回复者后,46 名参与者(男性 15 人,女性 31 人)被纳入分析。平均(±SD)随访时间为 103±17 个月(中位数 107,范围 68~154),平均(±SD)年龄为 31±8 岁。10 名 BRCA1/2 基因突变携带者罹患乳腺癌,1 名罹患卵巢癌,3 名罹患其他癌症。根据指南建议,6 名 BRCA1/2 基因突变携带者(19.4%)每年接受乳腺癌监测,但没有人接受卵巢癌或前列腺癌监测。三名携带者(9.7%)使用了乳腺癌化学预防方法。只有一名 BRCA1/2 基因突变携带者进行了降低风险的输卵管切除术。在未受影响的韩国 BRCA1/2 基因突变携带者中,乳腺癌/卵巢癌监测、化学预防和降低风险手术的比例较低。鉴于该人群罹患乳腺癌的风险相对较高,因此需要制定策略鼓励他们积极参与降低风险的活动。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current oncology
Current oncology ONCOLOGY-
CiteScore
3.30
自引率
7.70%
发文量
664
审稿时长
1 months
期刊介绍: Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.
期刊最新文献
Metabolic Complete Response of Metastatic Oncogene-Negative, PDL1-Negative Non-Small Cell Lung Cancer After Chemo-Immunotherapy and Radiotherapy: A Case Report. Rural Versus Urban Genitourinary Cancer Incidence and Mortality in Pennsylvania: 1990-2019. Let It Grow: The Role of Growth Factors in Managing Chemotherapy-Induced Cytopenia. A Longitudinal Multimodal Imaging Study in Patients with Temporo-Insular Diffuse Low-Grade Tumors: How the Inferior Fronto-Occipital Fasciculus Provides Information on Cognitive Outcomes. Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1